Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration
Srinivasa R. Rao et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Tumor-infiltrating Immune Cells in H&E-stained Sections of Colorectal Cancer Tissue as a Reasonable Immunological Biomarker
Shinji Matsutani et al.
ANTICANCER RESEARCH (2018)
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
Silvia Hernandez-Llodra et al.
ONCOTARGET (2017)
The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model
Monique H. M. Melis et al.
ONCOTARGET (2017)
Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer
Gretchen K. Hubbard et al.
CANCER RESEARCH (2016)
Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion
Ji-Youn Sung et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer
Ram S. Mani et al.
CELL REPORTS (2016)
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon
Dong Gao et al.
PLOS ONE (2016)
Inositol Hexaphosphate Inhibits Tumor Growth, Vascularity, and Metabolism in TRAMP Mice: A Multiparametric Magnetic Resonance Study
Komal Raina et al.
CANCER PREVENTION RESEARCH (2013)
Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course
Sven Perner et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
Yu Chen et al.
NATURE MEDICINE (2013)
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53
J. Kim et al.
ONCOGENE (2012)
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
Nicola J. Clegg et al.
PLOS ONE (2011)
Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts
B. G. Barwick et al.
BRITISH JOURNAL OF CANCER (2010)
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
Raquel Esgueva et al.
MODERN PATHOLOGY (2010)
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements
Michael C. Haffner et al.
NATURE GENETICS (2010)
Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status
K. Mwamukonda et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2010)
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis
Kari Rostad et al.
APMIS (2009)
TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort
Andrew D. Darnel et al.
CANCER BIOLOGY & THERAPY (2009)
Genome-Wide Linkage Analysis of TMPRSS2-ERG Fusion in Familial Prostate Cancer
Matthias D. Hofer et al.
CANCER RESEARCH (2009)
TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
Anuradha Gopalan et al.
CANCER RESEARCH (2009)
Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer
Chunru Lin et al.
CELL (2009)
Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer
Karin G. Hermans et al.
CLINICAL CANCER RESEARCH (2009)
Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States
Juan-Miguel Mosquera et al.
CLINICAL CANCER RESEARCH (2009)
Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results
L. Bonaccorsi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma
Roula Albadine et al.
MODERN PATHOLOGY (2009)
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
Jennifer C. King et al.
NATURE GENETICS (2009)
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Brett S. Carver et al.
NATURE GENETICS (2009)
Interactions between Cells with Distinct Mutations in c-MYC and Pten in Prostate Cancer
Jongchan Kim et al.
PLOS GENETICS (2009)
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer
Liesel M. FitzGerald et al.
BMC CANCER (2008)
Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas:: retrospective analysis of 55 formalin-fixed and paraffin-embedded
Cecile Rouzier et al.
CANCER GENETICS AND CYTOGENETICS (2008)
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model
Komal Raina et al.
CANCER RESEARCH (2008)
Pleiotropic Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene Transcripts
Jianghua Wang et al.
CANCER RESEARCH (2008)
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer
Rohit Mehra et al.
CANCER RESEARCH (2008)
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis
Outi R. Saramaki et al.
CLINICAL CANCER RESEARCH (2008)
Delineation of TMPRSS2-ERG splice variants in prostate cancer
Ying Hu et al.
CLINICAL CANCER RESEARCH (2008)
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
Maisa Yoshimoto et al.
MODERN PATHOLOGY (2008)
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation
C. Sun et al.
ONCOGENE (2008)
A causal role for ERG in neoplastic transformation of prostate epithelium
Olga Klezovitch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Role of the TMPRSS2-ERG gene fusion in prostate cancer
Arul M. Chinnaiyan
NEOPLASIA (2008)
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer
Bungo Furusato et al.
MODERN PATHOLOGY (2008)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G. Attard et al.
ONCOGENE (2008)
Recurrent gene fusions in prostate cancer
Chandan Kumar-Sinha et al.
NATURE REVIEWS CANCER (2008)
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
R. K. Nam et al.
BRITISH JOURNAL OF CANCER (2007)
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model
Komal Raina et al.
CANCER RESEARCH (2007)
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer:: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues
Jiangling J. Tu et al.
MODERN PATHOLOGY (2007)
Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression
Robert K. Nam et al.
CANCER BIOLOGY & THERAPY (2007)
TMPRSS2:: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
Sven Perner et al.
CANCER RESEARCH (2006)
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer
Jianghua Wang et al.
CANCER RESEARCH (2006)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Share Paper
